RECEIVED CENTRAL FAX CENTES

APR 0 2 700





9360 Towne Centre Drive San Diego, CA 92121 858-552-2200 (General #) 858-552-1936 (LEGAL FAX)

W3 4	COTACTI	TO 0	CTD A	TAJC: N	MISSION
НΔ		. P . I	KA	11221	moorus.

TO:

Examiner Karen Cochrane Carlson

FAX NO.:

(703) 872-9306

FROM: James E. Butler

PHONE NO.:

(858) 458-8564

Reg. No. 40,931

FAX NO.:

(858) 552-1936

cc:

Milan Vinnola, Arnold & Porter

FAX NO.:

(202) 942-5999

DATE: April 2, 2004

RE:

Serial No. 09/889,330

Number of pages being transmitted (including this cover sheet): _2__ including:

Response to Restriction Requirement (1 pg.)

If you do not receive all of the pages, please call Cassandra Peters at 858-458-8465. Thank you.

PLEASE DELIVER IMMEDIATELY!

This facsimile and the information it contains are intended to be a confidential communication only to the person or entity to whom it is addressed. If you have received this facsimile in error, please notify us by telephone and return the original fax to this office by mail.

COMMENTS:

	Please acknowle	dge receipt by	y signing	and faxing	back a	copy of
this	transmittal form.	Thank you.				

Received:	 Time:	

Pg 2of2

Patent Atty Docket No. 249/146US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kolterman et al. Serial No.: 09/889,330

Group Art Unit: 1653 Confirmation No.: 2741

Filed: December 27, 2001

For: Novel Exendin Agonist Formulations and Methods of Administration Thereof

Examiner: Samuel W. Liu

Response to Restriction Requirement

To the Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In response to the Office action mailed March 5, 2004 requiring restriction under 35 U.S.C. 121 and 372, Applicants hereby elect Group I, claims 1-42, drawn to pharmaceutical compositions comprising an exendin or an exendin agonist peptide.

Applicants believe that no fee is due in connection with this response. If Applicants are in error, the Commissioner is hereby authorized to charge any underpayment or credit any overpayment during the pendency of this application to Deposit Account No. 01-0535.

Respectfully submitted,

James E. Butler, Ph.D., Reg. No. 40,931

Amylin Pharmaceuticals, Inc. 9360 Towne Centre Drive San Diego, CA 92121 (858) 458-8564

Emas & Butter

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that the above Response to Restriction Requirement in the application of Kolterman et al., Serial No. 09/889,330, filed December 27, 2001, is being submitted to the Commissioner for Patents, Washington DC by facsimile transmission to telephone number 703-872-9306 on this 2nd day of April, 2004.

Canandra Peters